Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America

Helio S Sader; Jennifer M Streit; Cecilia G Carvalhaes; Michael D Huband; Michael A Pfaller

doi:10.1016/j.jgar.2018.11.013

Back

Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America

Journal article

Peer reviewed

Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America

Helio S Sader, Jennifer M Streit, Cecilia G Carvalhaes, Michael D Huband and Michael A Pfaller

Journal of global antimicrobial resistance., Vol.17, pp.103-108

06/2019

DOI: 10.1016/j.jgar.2018.11.013

PMID: 30458298

View Online

Abstract

Ceftaroline fosamil is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). This study evaluated the frequency and antimicrobial susceptibility of organisms isolated from patients hospitalised with community-acquired (CA) SSSI in Europe, the Asia-Pacific region (APAC) and Latin America (LATAM). Isolates (n=5120) were consecutively collected from patients hospitalised with CA-SSSI in 2014-2016 from 63 medical centres in 41 nations, stratified as Western Europe (20 centres/10 nations), Eastern Europe and the Mediterranean region (E-EUR; 16 centres/12 nations), APAC (16 centres/10 nations) and LATAM (11 centres/9 nations). Isolates obtained from outpatients or <48h after hospitalisation were considered CA. Organisms were tested for susceptibility by reference broth microdilution in a central laboratory. S. aureus was the most common CA-SSSI organism in all regions, except LATAM, and represented 43.3% of the overall collection. MRSA rates varied from 15.8% (E-EUR) to 21.4% (APAC), being 18.5% overall. In general, 98.9% of S. aureus and 94.2% of MRSA isolates were susceptible to ceftaroline, with 99.5% of MRSA isolates inhibited at ≤2mg/L (0.5% resistant). Escherichia coli (14.2%) and β-haemolytic streptococci (BHS) (8.2%) ranked second and third overall, respectively, with wide regional variation. BHS isolates were highly susceptible to ceftaroline (highest MIC, 0.03mg/L), but exhibited decreased susceptibility to tetracycline and erythromycin. The frequency and antimicrobial susceptibility of CA-SSSI bacteria varied broadly by geographic region. Ceftaroline exhibited potent activity against S. aureus (including MRSA), BHS and ceftriaxone-susceptible Enterobacterales isolates.

Community-acquired skin and skin-structure infection

ABSSSI

Ceftaroline

Staphylococcus aureus

MRSA

β-Haemolytic streptococci

Details

Title: Subtitle: Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America
Creators: Helio S Sader - JMI Laboratories
Jennifer M Streit - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Michael D Huband - JMI Laboratories
Michael A Pfaller - JMI Laboratories
Resource Type: Journal article
Publication Details: Journal of global antimicrobial resistance., Vol.17, pp.103-108
DOI: 10.1016/j.jgar.2018.11.013
PMID: 30458298
NLM abbreviation: J Glob Antimicrob Resist
ISSN: 2213-7165
eISSN: 2213-7173
Grant note: DOI: 10.13039/100004319, name: Pfizer
Language: English
Date published: 06/2019
Academic Unit: Epidemiology; Pathology
Record Identifier: 9984185180402771

Metrics

15 Record Views

13 Times Cited - Web of Science